Gilead's landmark CAR-T approval leaves Bristol Myers Squibb scrambling for second place - Endpoints News

You’ve got to be quicker than that, Bristol Myers Squibb. Gilead’s Kite scored a landmark approval for Yescarta in large B-cell lymphoma (LBCL) on Friday, making it the first CAR-T available in the second-line lymphoma setting. The news comes just a few month…

Sanofi is looking outside for advice and accountability on its diversity, equity and inclusion initiatives. Three of the board members on its newly created Sanofi DE&I Board aren’t employed by th… [+667 chars]

full article...